Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Rulemaking To-Do List Includes Clarifying Citizen Petitions And Orphan Drug Designations

Executive Summary

FDA pending actions include proposed rules on the handling of citizen petitions, eligibility for orphan drug designation and post-market safety reporting for combination products.

You may also be interested in...

Drug Shortage Rules Surface In Latest FDA Regulatory Agenda

FDA has yet to prognosticate on a schedule for other FDASIA-mandated regulations; HHS says that FDA’s priorities for the coming year will involve devices and food, as well as promoting international regulatory cooperation.

Drug Sample Distribution Reporting Deadline Extended By FDA

FDA is giving manufacturers six more months to provide HHS with information on the distribution of drug samples as it plans further guidance; the Affordable Care Act mandated that the data be submitted by April 1.

Orphan Disclosures Could Increase Under Tweaks Proposed By FDA

Agency considering whether to tell public if sponsors have submitted annual product development reports as part of proposed rule clarifying portions of 1992 Orphan Drug Regulations.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts